Epidemiology and Infection
- Epidemiology and Infection / Volume 139 / Issue 06 / June 2011, pp 826-835
- Copyright © Cambridge University Press 2010
- DOI: http://dx.doi.org/10.1017/S0950268810001512 (About DOI), Published online: 29 June 2010
Poliomyelitis
Effect on seroprevalence of anti-poliovirus antibodies and on vaccination coverage of the implementation of a DTwP-IPV-Hib vaccination programme in a South American city
S. V. NATESa1, M. FRIASa2, S. BELFIOREa2, M. B. ISAa1, L. C. MARTINEZa1, R. CHUITa3, J. ARMONIa4 and C. LUXEMBURGERa5 c1
a1 Instituto de Virología ‘Dr. J. M. Vanella’, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Argentina
a2 Direccion de Epidemiologia, Ministerio de Salud de la Provincia de Córdoba, Argentina
a3 Catedra de Medicina Preventiva y Social de la Universidad Nacional de Córdoba, Argentina
a4 Sanofi Pasteur, Buenos Aires, Argentina
a5 Sanofi Pasteur, Lyon, France
SUMMARY
Vaccination coverage and seroprevalence of poliovirus antibodies were assessed in Argentinean children (aged 8–12 and 19–21 months) living in Cordoba City pre-/post-implementation of a DTwP-IPV-Hib vaccination programme, and compared to those of controls from neighbouring populations receiving a full oral poliovirus vaccine schedule. Vaccination coverage was higher in control areas pre-intervention; this increased post-intervention in Cordoba (>90%) but not in control areas. Poliovirus types 1 and 2 seroprotection rates were >97% in all groups pre-/post-intervention. Type 3 seroprotection rates were generally lower, but increased post-intervention in Cordoba becoming significantly higher than control rates. Anti-type 1 and 3 antibody titres increased twofold and sevenfold, respectively, post-intervention, whereas anti-type 2 antibody titres decreased ~40% in the 8–12 months group. All titres increased in the 19–21 months post-intervention group. The introduction of a three-dose primary DTwP-IPV-Hib schedule maintained protection against poliovirus types 1 and 2, and increased protection against type 3, while vaccine coverage in the study area increased.
(Accepted May 26 2010)
(Online publication June 29 2010)
Correspondence:
c1 Author for correspondence: Dr C. Luxemburger, 2 avenue du pont Pasteur, F-69367 Lyon Cedex 07, France. (Email: christine.luxemburger@sanofipasteur.com)
